Pharmacokinetic interactions between chloroquine, sulfadoxine and pyrimethamine and their bioequivalence in a generic fixed-dose combination in healthy volunteers in Uganda

African Health Sciences

Volumn 6, Issue 2, 2006, Pages 86-92

  Obua, Celestino ^a,b   Ntale, M ^a,b   Lundblad, M S ^b   Mahindi, M ^b   Gustafsson, L L ^b   Ogwal Okeng, J W ^a   Anokbonggo, W W ^a   Hellgren, U ^b  

^a MAKERERE UNIVERSITY   (Uganda)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bioequivalence; Chloroquine; Pharmacokinetic interactions; Pyrimethamine; Sulfadoxine

Indexed keywords

CHLOROQUINE; FANSIDAR; HOMAPAK; PYRIMETHAMINE; SULFADOXINE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG FORMULATION; FEMALE; GOOD MANUFACTURING PRACTICE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UGANDA; ULTRAVIOLET RADIATION; UNSPECIFIED SIDE EFFECT; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; ANTIMALARIALS; BIOLOGICAL AVAILABILITY; CHLOROQUINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG INTERACTIONS; DRUGS, GENERIC; FEMALE; HUMANS; MALE; PROBABILITY; PYRIMETHAMINE; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; SULFADOXINE; THERAPEUTIC EQUIVALENCY; UGANDA;

EID: 34347370662     PISSN: 16806905     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. White NJ. Antimalarial drug resistance. J Clin Invest 2004; 113:1084-1092.
2. Giao PT, de Vries PJ. Pharmacokinetic interactions of antimalarial agents. Clin Pharmacokinet 2001; 40: 343-373.
3. Maitland K, Makanga M, Williams TN. Falciparum malaria: Current therapeutic challenges. Curr Opin Infect Dis 2004; 17:405-412.
4. GlobalHealthReporting.org Malaria: WHO announces shortage of "most effective" malaria drug through March 2005. http://www.kaisernetwork.org/daily_reports/rep_index.cfm
5. Implementation Guidelines for the Home Based Management of Fever Strategy. 1st Ed. Kampala: Ministry of Health, Uganda. 2002.
6. Africa Malaria Report. [http://www.rbm.who.int/amd2003/amr2003/ch1-3.htm]
7. Kilian AH, Tindyebwa D, Gulck T, Byamukama W, Rubaale T, Kabagambe G, Korte R. Attitude of women in western Uganda towards pre-packed, unit-dosed malaria treatment for children. Trop Med Int Health 2003;8:431-8.
8. Nsungwa-Sabiiti J, Tomson G, Pariyo G, Ogwal-Okeng J, Peterson S. Community effectiveness of malaria treatment - a long way from Abuja targets. Annals of Tropical Paediatrics, 2005;25:91-100.
9. McGregor A. Counterfeit drugs flood developing world. Lancet 1997;350:1690.
10. Rozendaal J. Fake antimalaria drugs in Cambodia, correspondence. Lancet 2001,357:890
11. Taylor RB, Shakoor O, Behrens RH, et al. Pharmacopoeial quality of drugs supplied by Nigerian pharmacies. Lancet 2001;357:1933-6.
12. Behrens RH, Awad AI, Taylor RB. Substandard and counterfeit drugs in developing countries. Tropical Doctor 2002;32:1-2.
13. Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and Applications. 3rd ed. Philadelphia: Lippincott Williams and Wilkins, 1995.
14. Handbook of Pharmaceutical Excipients, 2nd Ed. London: The Pharmaceutical Press, 1994.
15. Rengelshausen J, Burhenne J, Fröhlich M, et al. Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria. Eur J Clin Pharmacol 2004; 60:709-715.
16. Grace JM, Aguilar AJ, Trotman KM, Peggins JO, Brewer TG. Metabolism of â-Arteether to Dihyroqinghaosu by Human Liver Microsomes and Recombinnant Cytochrome P450. Drug Metab Dispos 1998;26:313-317
17. Ali HM. Reduced ampicillin bioavailability following oral coadministration with chloroquine. J Antimicrob Chemother 1985;15:781-784
18. Bergqvist Y, Eriksson M. Simultaneous determination of pyrimethamine and sulfadoxine in human plasma by highperformance liquid chromatography. Trans R Soc Trop Med Hyg 1985; 79: 297-301.
19. Minzi OMS, Rais M, Svensson JO, Gustafsson LL, Ericsson O. High-performance liquid chromatographic method for the determination of amodiaquine, chloroquine and their metabolites in biological samples. J Chromatogr B 2003; 783: 473-840.
20. EMEA. Evaluation of Medicines for Human Use: Committee for Proprietory Medicinal Products-Note for Guidance on the Investigation of Bioavailability and Bioequivalence. 2001. CPMP/EWP/QWP/1401/98
21. Attaran A, Barnes KI, Curtis C, d'Alessandro U, Fanello CI, Galinski MR, Kokwaro G, Looareesuwan S, Makanga M, Mutabingwa TK, Talisuna A, Trape JF & Watkins WM. (2004) WHO, the Global Fund, and medical malpractice in malaria treatment. Lancet 363, 237-40.
22. World Health Organization. WHO Guidelines for treatment of malaria. WHO/HTM/MAL/2006.1108. WHO 2006. Geneva.
23. Stockley's Drug Interactions, 6th Ed. London; Pharmaceutical Press; 2002;1-14.
24. Brundtland GH. Essential Medicines: 25 years of better health. JAMA 2002;288:3102.
25. Quick JD, Hogerzeil HV, Velásquez G, Rago L. Twenty-five years of essential medicines. Bull WHO 2002;80:913-914.